Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
AssigneeNew England Deaconess Hospital Corporation
InventorsCarol A. Toth, Peter Thomas
Life of this patent
Estimating the term…
Abstract
Disclosed is a glycoprotein, CORA, which has a binding affinity for carcinoembryonic antigen (CEA). This glycoprotein is a marker for carcinoma, and can be characterized by having a molecular weight of about 46,000-50,000 daltons, an isoelectric point of about 3.0-3.5, a carbohydrate content of about 25-35% by weight, reactivity with antisera raised thereto, and substantially no reactivity with antisera raised to nonspecific cross-reacting antigen (NCA) or to CEA. Also disclosed are a hybridoma which produces a monoclonal antibody to CORA, the monoclonal antibody to CORA, and a device, kit, and method for detecting and monitoring carcinoma.
Claims8
Essentially purified and isolated carcinoma orosomucoid-related antigen, a glycoprotein having a binding affinity for carcinoembryonic antigen, said glycoprotein having:
- (a) a molecular weight of about 46,000-50,000 daltons;
- (b) an isoelectric point of about 3.0-3.5;
- (c) a carbohydrate content of about 25-35% by weight;
- (d) reactivity with a monoclonal antibody ND5 raised thereto;
- (e) no cross-reactivity with antisera raised to nonspecific cross-reacting antigen;
- and
- (f) no cross-reactivity with antisera raised to carcinoembryonic antigen.
An essentially purified and isolated marker for carcinoma consisting of carcinoma orosomucoid-related antigen,
- a glycoprotein having a molecular weight of approximately 46,000-50,000 daltons, an isoelectric point of approximately 3.0-3.5, a carbohydrate content of approximately 30% by weight, reactivity with a monoclonal antibody ND5 raised thereto, no cross-reactivity with antisera raised to carcinoembryonic antigen or to nonspecific cross-reacting antigen, and a binding affinity for carcinoembryonic antigen.
Dependencies are inferred from the claim text.